A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) | Completed
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)

Trial Source

There is no location for this trial

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Health Conditions
  • Arthritis, Juvenile Rheumatoid
Unfortunately contact details are not available for this trial.
Primary Contact Details
Completed
Recruitment Status
NCT00279747
Primary Trial ID Number
Summary
A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.
Research Details
  • Objective: In an international, multicenter, double-blind, randomized clinical trial we evaluated the short-term (3 months) and long term (12 months) efficacy and safety of two doses of meloxicam oral suspension compared with naproxen in children with oligo and polyarticular course juvenile idiopathic arthritis (JIA). Methods: Children with active oligo or polyarticular course JIA, requiring therapy with an NSAID were eligible for this trial. Patients were randomly allocated to therapy with meloxicam oral suspension 0.125 mg/kg body weight in single daily dose, meloxicam 0.25 mg/kg body weight in single daily dose, or naproxen 10 mg/kg body weight in two daily doses. The trial drugs were administered in a double-blind, double-dummy design for up to 12 months. Response rates were determined according to the American College of Rheumatology Pediatric 30% definition of improvement (ACR Ped 30). Safety parameters were assessed by evaluation of the adverse events in the 3 groups. Study Hypothesis: The null hypothesis of interest is that the magnitude of response with regard to the primary endpoint is equivalent between the treatment groups. The alternative is that there is any difference (two-sided) between any of the treatment groups. Comparison(s): Naproxen oral suspension 10 mg/kg body weight.
Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Study Type
Interventional
Intervention
Drug : meloxicam 0.25 mg/kg, Drug : meloxicam 0.125 mg/kg, Drug : naproxen 10 mg/kg

Study Arm Groups : , ,

Intervention Type
See Interventions above
Primary Outcome Measures
  • Response rates according to ACR Ped 30; after 12 weeks of treatment
Secondary Outcome Measures
  • Global assessment of overall disease activity by investigator; up to 12 months; Parent global assessment of overall well-being; up to 12 months; Assessment of functional disability by means of Childhood Health Assessment Questionnaire (CHAQ); up to 12 months; Number of joints with active arthritis; up to 12 months; Number of joints with limited range of motion; up to 12 months; Erythrocyte Sedimentation Rate (ESR); up to 12 months; Parent global assessment of arthritis; up to 12 months; Parent global assessment of pain; up to 12 months; Children's assessment of discomfort; up to 12 months; Change in functional classification (Steinbrocker classification); up to 12 months; Final global assessment of efficacy by parent; week 12, 12 months; Final global assessment of efficacy by investigator; week 12, 12 months; Withdrawals due to inadequate efficacy; up to 12 months; Paracetamol / acetaminophen consumption; up to 12 months; Final global assessment of tolerability by parent; week 12, 12 months; Final global assessment of tolerability by investigator; week 12, 12 months; Incidence and intensity of adverse events (AEs); 12 months; Incidence of laboratory adverse events; 12 months; Withdrawal due to adverse event; 12 months; Duration of hospital stay due to gastrointestinal serious adverse event (GI-SAE); week 12, 12 months; Duration of hospital stay due to adverse events related to trial drug administration; week 12, 12 months; Additional visits to a physician due to gastrointestinal adverse event (GI-AE); week 12, 12 months
Publication(s)
Sorry, this information is not available
Result Reports
This is available on the Clinicaltrials.gov website
Gender
Both
Age Range
2 Years - 16 Years
Who Can Participate
Patients
Number of Participants
Sorry, this information is not available
Participant Inclusion Criteria
  • Inclusion Criteria:
  • - Male or female outpatients and inpatients aged 2 to 16 years
  • - Diagnosis of idiopathic arthritis of childhood by ILAR criteria:
  • - Age of onset less than 16 years
  • - Arthritis in one or more joints defined as swelling, or - if no swelling is
  • present - limitation in range of joint movement with joint pain or tenderness,
  • which is not due to primary mechanical disorders
  • - Duration of the disease > 6 weeks
  • - Type of onset of disease during the first 6 months classified as polyarthritis
  • (5 joints or more; rheumatoid factor positive or negative), oligoarthritis (4
  • joints or fewer) or systemic arthritis
  • - Oligoarthritic, extended oligoarthritic or polyarthritic current course of disease
  • - Active arthritis as defined above of at least 2 joints
  • - At least 2 other abnormal variables of any of the 5 remaining core set parameters.
  • The physician and the parent ratings must be at least 10 mm on a 100 mm VAS scale and
  • the CHAQ score more than 0.
  • - Patients requiring therapy with NSAIDs, i.e., the patient fits into one of the
  • following categories:
  • - New onset patient
  • - Patient in remission, but experiencing a flare and now requiring an NSAID
  • - Patient with insufficient therapeutic effect (ITE) or intolerability to another
  • NSAID (other than Naproxen) and now must be changed
  • - Written informed permission given by the parent(s) or the subjects legally authorised
  • representative in accordance with local legislation and ICH GCP
  • - Active assent given by the patient if the child is capable of understanding the given
  • information (applies to children who have reached an intellectual age of 7 years or
  • greater)
  • Exclusion Criteria:
  • - Patients with systemic course of JRA (intermittent fever with or without rash or
  • other organ involvement) or with current systemic involvement
  • - All rheumatic diseases not covered by the inclusion criteria
  • - Any finding indicating that the patient has a clinically significant other disease
  • than JRA at the time of enrollment
  • - Patients with abnormal, clinically relevant laboratory values not related to their
  • JRA
  • - Pregnancy or breast feeding
  • - Women of childbearing potential not using adequate contraception precaution:
  • attention should be drawn to reports that NSAIDs were reported to decrease the
  • effectiveness of intrauterine devices (R95-0164)
  • - History of bleeding disorders, gastrointestinal bleeding or cerebrovascular bleeding
  • - Active peptic ulcer within the last 6 months
  • - Treatment with more than one SAARD/DMARD (slow-acting antirheumatic
  • drug/disease-modifying antirheumatic drug) during the last 3 months prior to study
  • entry
  • - Change in treatment with SAARDs/DMARDs during the last 3 months prior to study entry
  • or intended change during the trial duration
  • - Change in treatment with corticosteroids during the last month prior to study entry
  • or intended change during the trial duration with exception of local therapy for
  • uveitis
  • - One of the following therapies during the last 3 months prior to study entry or their
  • intended use during the trial treatment period
  • - Systemic treatment (except for intra-articular injections) with corticosteroids
  • at a dose higher than 10 mg/day or 0.2 mg/kg/day (prednisone equivalent),
  • respectively (whichever is lower)
  • - Treatment with hydroxychloroquine at a dose higher than 10 mg/kg/day
  • - Treatment with cyclosporine at a dose higher than 5 mg/kg/day
  • - Treatment with methotrexate at a dose higher than 15 mg/m2/week
  • - Treatment with other cytotoxic agents, gold compounds, D-penicillamine, Enbrel
  • (etanercept), biologic agents and experimentals
  • - Intra-articular injections of corticosteroids during the last month prior to study
  • entry and intended injections during the first 4 weeks of the trial treatment period
  • - Concomitant administration of other NSAIDs (including topical forms for skin with
  • exception of local therapy for uveitis) or analgesic agents except paracetamol or
  • acetaminophen
Participant Exclusion Criteria
This is in the inclusion criteria above
Trial Location(s)
GSK Investigational Site
London
WC1N 3JH
New Cross Hospital
Wolverhampton
Midlands
WV10 0QP
Manchester
M9 7AA
Trial Contact(s)
Primary Trial Contact
Sorry, this information is not available
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
Austria, Belgium, France, Germany, Italy, Russian Federation, United Kingdom
Scientific Title
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.
EudraCT Number
Not available for this trial
Funder(s)
    Sorry, this information is not available
Other Study ID Numbers
107.208
Sponsor(s)
Boehringer Ingelheim
Key Dates

Recruitment Start Date

Sep 2000

Recruitment End Date

Jan 2003

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date Assigned

19 Jan 2006

Last Updated

31 Oct 2013